1 Haslam, DW & James, WP (2005) Obesity. Lancet 366, 1197–1209.
2 Maury, E & Brichard, SM (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314, 1–16.
3 Hotamisligil, GS, Shargill, NS & Spiegelman, BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87–91.
4 Neal, MD, Leaphart, C, Levy, R, et al. (2006) Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 176, 3070–3079.
5 Cani, PD, Bibiloni, R, Knauf, C, et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470–1481.
6 Cani, PD, Delzenne, NM, Amar, J, et al. (2008) Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathol Biol (Paris) 56, 305–309.
7 Tilg, H & Moschen, AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6, 772–783.
8 Zhang, Y, Proenca, R, Maffei, M, et al. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432.
9 Friedman, JM & Halaas, JL (1998) Leptin and the regulation of body weight in mammals. Nature 395, 763–770.
10 Bates, SH & Myers, MG Jr (2003) The role of leptin receptor signaling in feeding and neuroendocrine function. Trends Endocrinol Metab 14, 447–452.
11 Ciardi, C, Tatarczyk, T, Tschoner, A, et al. (2010) Effect of postprandial lipemia on plasma concentrations of A-FABP, RBP-4 and visfatin. Nutr Metab Cardiovasc Dis 20, 662–668.
12 Havel, PJ, Kasim-Karakas, S, Mueller, W, et al. (1996) Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 81, 4406–4413.
13 Guerci, B, Hadjadj, S, Quilliot, D, et al. (2000) No acute response of leptin to an oral fat load in obese patients and during circadian rhythm in healthy controls. Eur J Endocrinol 143, 649–655.
14 Despres, JP & Lemieux, I (2006) Abdominal obesity and metabolic syndrome. Nature 444, 881–887.
15 Green, H & Kehinde, O (1975) An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. Cell 5, 19–27.
16 Montague, CT, Farooqi, IS, Whitehead, JP, et al. (1997) Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387, 903–908.
17 Campfield, LA, Smith, FJ, Guisez, Y, et al. (1995) Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269, 546–549.
18 Halaas, JL, Gajiwala, KS, Maffei, M, et al. (1995) Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269, 543–546.
19 Pelleymounter, MA, Cullen, MJ, Baker, MB, et al. (1995) Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269, 540–543.
20 Maffei, M, Halaas, J, Ravussin, E, et al. (1995) Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1, 1155–1161.
21 Ostlund, RE Jr, Yang, JW, Klein, S, et al. (1996) Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. J Clin Endocrinol Metab 81, 3909–3913.
22 Laimer, M, Ebenbichler, CF, Kaser, S, et al. (2002) Weight loss increases soluble leptin receptor levels and the soluble receptor bound fraction of leptin. Obes Res 10, 597–601.
23 Sandhofer, A, Laimer, M, Ebenbichler, CF, et al. (2003) Soluble leptin receptor and soluble receptor-bound fraction of leptin in the metabolic syndrome. Obes Res 11, 760–768.
24 Fried, SK, Ricci, MR, Russell, CD, et al. (2000) Regulation of leptin production in humans. J Nutr 130, 3127S–3131S.
25 Lester, MR (1995) Sulfite sensitivity: significance in human health. J Am Coll Nutr 14, 229–232.
26 Gunnison, AF & Palmes, ED (1976) A model for the metabolism of sulfite in mammals. Toxicol Appl Pharmacol 38, 111–126.
27 Gunnison, AF & Jacobsen, DW (1987) Sulfite hypersensitivity. A critical review. CRC Crit Rev Toxicol 17, 185–214.
28 Kim, SY, Kim, CH, Yoo, HJ, et al. (1999) Effects of radical scavengers and antioxidant on ischemic acute renal failure in rabbits. Ren Fail 21, 1–11.
29 Nettis, E, Colanardi, MC, Ferrannini, A, et al. (2004) Sodium benzoate-induced repeated episodes of acute urticaria/angio-oedema: randomized controlled trial. Br J Dermatol 151, 898–902.
30 Asero, R (2006) Sodium benzoate-induced pruritus. Allergy 61, 1240–1241.
31 McCann, D, Barrett, A, Cooper, A, et al. (2007) Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. Lancet 370, 1560–1567.
32 Maier, E, Kurz, K, Jenny, M, et al. (2010) Food preservatives sodium benzoate and propionic acid and colorant curcumin suppress Th1-type immune response in vitro. Food Chem Toxicol 48, 1950–1956.
33 De Kimpe, SJ, Anggard, EE & Carrier, MJ (1998) Reactive oxygen species regulate macrophage scavenger receptor type I, but not type II, in the human monocytic cell line THP-1. Mol Pharmacol 53, 1076–1082.
34 Epstein, J, Sanderson, IR & Macdonald, TT (2010) Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 103, 1545–1557.
35 Aggarwal, BB, Kumar, A & Bharti, AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23, 363–398.
36 Hatcher, H, Planalp, R, Cho, J, et al. (2008) Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65, 1631–1652.
37 Jang, EM, Choi, MS, Jung, UJ, et al. (2008) Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism 57, 1576–1583.
38 Seo, KI, Choi, MS, Jung, UJ, et al. (2008) Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 52, 995–1004.
39 Weisberg, SP, Leibel, R & Tortoriello, DV (2008) Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 149, 3549–3558.
40 Menon, VP & Sudheer, AR (2007) Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595, 105–125.
41 Ejaz, A, Wu, D, Kwan, P, et al. (2009) Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr 139, 919–925.
42 Kwon, Y & Magnuson, BA (2009) Age-related differential responses to curcumin-induced apoptosis during the initiation of colon cancer in rats. Food Chem Toxicol 47, 377–385.
43 Cruz, MT, Duarte, CB, Goncalo, M, et al. (2001) LPS induction of I kappa B-alpha degradation and iNOS expression in a skin dendritic cell line is prevented by the janus kinase 2 inhibitor, Tyrphostin b42. Nitric Oxide 5, 53–61.
44 Unno, Y, Akuta, T, Sakamoto, Y, et al. (2006) Nitric oxide-induced downregulation of leptin production by 3T3-L1 adipocytes. Nitric Oxide 15, 125–132.
45 Jones, E, Adcock, IM, Ahmed, BY, et al. (2007) Modulation of LPS stimulated NF-kappaB mediated nitric oxide production by PKCepsilon and JAK2 in RAW macrophages. J Inflamm (Lond) 4, 23.
46 Kapur, S, Marcotte, B & Marette, A (1999) Mechanism of adipose tissue iNOS induction in endotoxemia. Am J Physiol 276, E635–E641.
47 Dobashi, K, Asayama, K, Nakane, T, et al. (2000) Troglitazone inhibits the expression of inducible nitric oxide synthase in adipocytes in vitro and in vivo study in 3T3-L1 cells and Otsuka Long-Evans Tokushima Fatty rats. Life Sci 67, 2093–2101.